🇺🇸 AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders

🇺🇸

As a dual-purpose, potential first-in-class, “pipeline-in-a-drug” candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process. ISM9077 was designed, evaluated and optimized utilizing Chemistry42’s integrated generative…

Source: prnewswire

Country: United States